Idursulfase

Idursulfase

Clinical data
AHFS/Drugs.com	monograph
Identifiers
CAS Registry Number	50936-59-9 Y
ATC code	A16AB09
DrugBank	DB01271 Y
UNII	5W8JGG2651 Y
KEGG	D04499 Y
ChEMBL	CHEMBL1201826 N
Chemical data
N (what is this?)  (verify)

Idursulfase (brand name Elaprase), manufactured by Shire, is a drug used to treat Hunter syndrome (also called MPS-II).^[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

It is one of the most expensive drugs ever produced, costing US$375,000 per patient per year.^[2][3]

References

1. ↑ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751. 
2. ↑ "Drug approved to treat rare but potentially deadly disease". Retrieved 2011-04-29. 
3. ↑ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010

External links

• idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)